866775-16-8

Usage

Uses

Used in Pharmaceutical Industry:
3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drug candidates. Its unique structure allows for the creation of molecules with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile is utilized as a building block for the synthesis of agrochemicals, contributing to the development of effective compounds for crop protection and enhancement of agricultural productivity.
Used in Specialty Chemicals Production:
3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile is employed in the production of dyes and pigments, where its chemical properties enable the creation of vibrant and stable colorants for various applications.
Used in Medicinal Chemistry Research:
As a starting material in medicinal chemistry research, 3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile is used for the exploration and development of novel drug candidates, providing a foundation for innovative therapeutic agents.
It is crucial to handle 3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile with care due to its potential health hazards. Proper ventilation and personal protective equipment are essential when working with 3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile to ensure safety.

Upstream product

• 544-92-3 copper(I) cyanide 
• 72587-15-6 2-chloro-3-nitro-5-(trifluoromethyl)pyridine 
• 33252-64-1 3-nitro-5-trifluoromethylpyridin-2-ol 
• 1214336-90-9 3-amino-6-(2,6-difluorophenyl)-5-trifluoromethyl-2-pyridinecarboxylicacid 

Downstream Products

• 866775-17-9 3-amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester 
• 866775-18-0 3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester 
• 1334546-83-6 3-amino-6-(2,4-dichlorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid 
• 1214370-77-0 3-amino-5-trifluoromethylpyridine-2-carboxylic acid 
• 1334547-21-5 3-amino-6-(4-fluorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid 
• 1334547-23-7 3-amino-6-(2,4-dichlorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid methyl ester 
• 1211515-30-8 3-amino-5-(trifluoromethyl)picolinonitrile 
• 1334546-80-3 3-amino-6-(4-fluorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)amide 
• 1427262-61-0 3-amino-6-bromo-N'-(2-phenylacetyl)-5-(trifluoromethyl)picolinohydrazide 
• 1427262-60-9 2-(5-benzyl-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine 
• 1427262-81-4 (R)-benzyl 2-(2-(3-amino-6-bromo-5-(trifluoromethyl)picolinoyl)hydrazinyl)-2-oxo-1-phenylethylcarbamate 
• 1427262-83-6 (R)-benzyl (5-(3-amino-6-bromo-5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(phenyl)methylcarbamate 
• 1427262-80-3 (R)-2-(5-(amino(phenyl)methyl)-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine 
• 1427400-35-8 methyl 3-amino-6-(4-fluorophenyl)-5-(trifluoromethyl)picolinate 

Relevant academic research and scientific papers

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be asso

Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Pyridine derivative PIM kinase inhibitor and preparation method therefor and application thereof in pharmacy

The present invention provides a PIM kinase inhibitor and a preparation method therefor and an application thereof. The PIM kinase inhibitor is a compound with the structural formula shown in the formula I (the formula is shown in description). The present invention further provides a stereoisomer, a tautomer and pharmaceutical salt of the compound shown in the formula I. According to the present invention, the compound has an obvious inhibition effect on kinase activity. The PIM kinase inhibitor can be used for preparing drugs for curing or preventing cancer, autoimmune diseases, allergic reaction diseases or organ transplant rejection resistance and the like, and the PIM kinase inhibitor has relatively large value in clinical application.

BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS

The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

PYRIDINE AMIDE DERIVATIVES

The present invention provides pyridine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory

Pyridine amide derivatives

The present invention provides pyridine amide derivatives which re? store or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, resp

PYRIDINE/PYRAZINE AMIDE DERIVATIVES

The present invention provides pyridine/pyrazine amide derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthm